Replies to post #22220 on RespireRx Pharmaceuticals Inc (fka RSPI)

[sps18]

Dow: -680(7.7%) COR: +0.03(4.4%)

[DewDiligence]

>Johnson & Johnson Is Latest FDA Casualty<

Never mind the ceftobiprole rejection—JNJ’s executives are ecstatic today. They just acquired the best neurotoxin drug candidate and they didn’t have to overpay to get it.